Beiying Ding

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · New England Journal of Medicine · 2018 · 3.3K citations · Full text

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

Paul D. Miller, Michael A. Bolognese, E. Michael Lewiecki et al. · Bone · 2008 · 562 citations

Bone Disease, Bone Health, Gynecology +9

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle, Richard S. Finn, Shukui Qin et al. · The Lancet Oncology · 2021 · 362 citations

Patient-reported Outcomes, Hepatology, Medicine +11

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

Andrea Necchi, Richard W. Joseph, Yohann Loriot et al. · Annals of Oncology · 2017 · 315 citations · Full text

Urology, Metastatic Urothelial Carcinoma, Post-progression Outcomes +7

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

Ian R. Reid, Paul D. Miller, Jacques P. Brown et al. · Journal of Bone and Mineral Research · 2010 · 249 citations · Full text